Regional (cavity) administration One Phase I/II Study of
intraperitoneal administration of GL-ONC1 in patients with advanced
peritoneal carcinomatosis has been completed. A Phase II study of
intraperitoneal administration of GL-ONC1 (Olvi-Vec) in heavily pretreated patients with platinum-resistant/refractory
ovarian cancer was completed. Positive clinical data have been reported in IGCS 2020 and ESMO 2020 conferences. A registration trial of Olvi-Vec(aka GL-ONC1)-primed immunochemotherapy is being planned. In a Phase I study, intra-pleural administration of GL-ONC1 is being evaluated in patients with
malignant pleural effusion, which is caused by cancer from malignant pleural
mesothelioma,
non-small cell lung cancer (NSCLC), or
breast cancer. In this trial GL-ONC1 infection of tumor cells was identified in 6 out of 8 patients with epithelioid malignant pleural mesothelioma.
Systemic (intravenous) administration Systemic administration of GL-ONC1 via intravenous injection was under investigation in multiple clinical trials: In one study, GL-ONC1 was administered to patients with advanced solid organ tumors as a monotherapy. In another completed study, GL-ONC1 was given in combination with radiation therapy and
cisplatin (CDDP) to patients with locoregionally advanced head and neck cancer. == References ==